Aeterna Zentaris second-quarter revenues lower to $5.

Aeterna Zentaris second-quarter revenues lower to $5 .6 million All amounts are in U.S. Dollars Aeterna Zentaris Inc. , a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010. April 5 Second One fourth 2010 Highlights Pipeline advancement Perifosine -, 2010: Perifosine receives U.S. Food and Drug Administration Fast Monitor Designation for the Stage 3 X-PECT + Perifosine Evaluation in Colorectal cancer tumor Treatment) registration trial. April 8 -, 2010: Initiation of the registration Phase 3 X-PECT study with perifosine. April 15 -, 2010: Positive Scientific Advice from the European Medications Company for the Stage 3 plan with perifosine in multiple myeloma.

About head and neck cancer Head and throat cancer may appear in over 30 different places in any of the cells or organs in the head and neck and is the sixth most frequently occurring cancer worldwide . Most head and throat cancers are squamous cell carcinomas over 90 percent of which communicate EGFR which is crucial for tumour growth. About ovarian cancer Each year approximately 204,000 fresh cases of ovarian cancers are diagnosed in females worldwide, with an estimated 125,000 dying of the disease each full year. One of the greatest challenges in the administration of ovarian cancer is that the majority of cases are not bought at an early stage since the tumour generally causes only nonspecific symptoms, attributed to non-serious causes commonly.